Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
Phase III Study of Daratumumab/rHuPH20 NSC- 810307 + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma MM Using Minimal Residual Disease to Direct Therapy Duration DRAMMATIC Study
A Phase I Study to Evaluate the Safety and Pharmacokinetic Profiles of CB-5339 in Participants with Relapsed/Refractory Acute Myeloid Leukemia, Intermediate or Higher-Risk Myelodysplastic Syndromes, bcr-abl negative Myeloproliferative, Myelodysplastic/Myeloproliferative Neoplasms and Multiple Myeloma
CARTITUDE-2: A Phase II, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell CAR-T Therapy Directed Against BCMA in Subjects with Multiple Myeloma
A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
Phase I, Open Label, Study of B-cell Maturation Antigen BCMA-directed CAR-T cells in Adult Patients with Multiple Myeloma
Master Screening and Reassessment Protocol MSRP for Tier Advancement in the NCI myeloMATCH Clinical Trials
A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone Dara-VCD Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis
Study Type: Treatment
Phase: III
NCTID: NCT06022939
Principal Investigator:
Muhammad Umair Mushtaq